Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling

Marc Zuckermann, Volker Hovestadt, Christiane B. Knobbe-Thomsen, Marc Zapatka, Paul A. Northcott, Kathrin Schramm, Jelena Belic, David T. W. Jones, Barbara Tschida, Branden Moriarity, David Largaespada, Martine F. Roussel, Andrey Korshunov, Guido Reifenberger, Stefan M. Pfister, Peter Lichter, Daisuke Kawauchi () and Jan Gronych ()
Additional contact information
Marc Zuckermann: German Cancer Research Center (DKFZ)
Volker Hovestadt: German Cancer Research Center (DKFZ)
Christiane B. Knobbe-Thomsen: Heinrich Heine University Düsseldorf
Marc Zapatka: German Cancer Research Center (DKFZ)
Paul A. Northcott: German Cancer Research Center (DKFZ)
Kathrin Schramm: German Cancer Research Center (DKFZ)
Jelena Belic: German Cancer Research Center (DKFZ)
David T. W. Jones: German Cancer Research Center (DKFZ)
Barbara Tschida: Masonic Cancer Center, University of Minnesota
Branden Moriarity: Masonic Cancer Center, University of Minnesota
David Largaespada: Masonic Cancer Center, University of Minnesota
Martine F. Roussel: Tumor Cell Biology, St Jude Children’s Research Hospital
Andrey Korshunov: University of Heidelberg
Guido Reifenberger: Heinrich Heine University Düsseldorf
Stefan M. Pfister: German Cancer Research Center (DKFZ)
Peter Lichter: German Cancer Research Center (DKFZ)
Daisuke Kawauchi: German Cancer Research Center (DKFZ)
Jan Gronych: German Cancer Research Center (DKFZ)

Nature Communications, 2015, vol. 6, issue 1, 1-9

Abstract: Abstract In vivo functional investigation of oncogenes using somatic gene transfer has been successfully exploited to validate their role in tumorigenesis. For tumour suppressor genes this has proven more challenging due to technical aspects. To provide a flexible and effective method for investigating somatic loss-of-function alterations and their influence on tumorigenesis, we have established CRISPR/Cas9-mediated somatic gene disruption, allowing for in vivo targeting of TSGs. Here we demonstrate the utility of this approach by deleting single (Ptch1) or multiple genes (Trp53, Pten, Nf1) in the mouse brain, resulting in the development of medulloblastoma and glioblastoma, respectively. Using whole-genome sequencing (WGS) we characterized the medulloblastoma-driving Ptch1 deletions in detail and show that no off-targets were detected in these tumours. This method provides a fast and convenient system for validating the emerging wealth of novel candidate tumour suppressor genes and the generation of faithful animal models of human cancer.

Date: 2015
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/ncomms8391 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms8391

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/ncomms8391

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().